Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 11, 2000, Pages 4258-4265

  Harman, S Mitchell ^a,c   Metter, E Jeffrey ^a   Blackman, Marc R ^b   Landis, Patricia K ^b   Carter, H Ballentine ^b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Kronos Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; STATISTICAL ANALYSIS;

EID: 0034527640     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.85.11.6990     Document Type: Article

References (53)

1. Autocrine growth factors and cancer
2. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors
3. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation
4. Insulin-like growth factors and cancer
5. Insulin-like growth factor binding proteins
6. IGF binding proteins: Regulation of cellular actions
7. Insulin-like growth factor-binding proteins in serum and other biological fluids: Regulation and functions
8. The insulin-like growth factors
9. Insulin-like growth factor binding protein (IGFBP) proteases: Functional regulators of cell growth
10. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells
11. Insulin-like growth factor-I receptors in human hyperplastic prostate tissue: Characterization, tissue localization, and their modulation by chronic treatment with a gonado tropin-releasing hormone analog
12. Benign prostatic hyperplasia and normal prostate aging: Differences in types I and II 5α-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not in insulin-like growth factor mRNA levels
13. IGF binding protein-3 secreted by the prostate adenocarcinoma cells (PC- 3): Differential effect on PC-3 and normal prostate cell growth
14. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia
15. Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-4 in human prostatic hyperplastic tissue: Gene expression and its cellular localization
16. Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: Evidence for an IGF-II autocrine growth loop
17. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer
18. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1
19. Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture
20. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease
21. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1
22. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma
23. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
24. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease
25. The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer
26. The clinical usefulness of prostate specific antigen: Update 1994
27. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
28. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer
29. Early detection of prostate cancer. I. Prior probability and effectiveness of tests
30. A retrospective and prospective overview of prostate-specific antigen
31. The insulin-like growth factor axis and prostate cancer: Lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model
32. Radioimmunoassays for IGFs and IGFBPs
33. A specific radioimmunoassay for insulin-like growth factor II: The interference of IGF binding proteins can be blocked by excess IGF-I
34. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: Its use for diagnosis of GH deficiency
35. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes
36. Serum insulin-like growth factor-I levels and prostate cancer risk-interpreting the evidence
37. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients
38. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: Correlation with serum prostate-specific antigen
39. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia
40. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia
41. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study
42. IGF-I and prostate cancer
43. M6P/IGF2 receptor: A candidate breast tumor suppressor gene
44. The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene
45. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate
46. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia
47. Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era
48. Age and racial distribution of prostatic intraepithelial neoplasia
49. Analysis of repeated markers used to predict progression of cancer
50. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen